Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1141 to 1155 of 1423 results for primary care

  1. Intermittent urinary catheters: catheter selection:- For patients performing intermittent self-catheterisation over the long term, what is the clinical and cost effectiveness of single-use non-coated versus single-use hydrophilic versus single-use gel reservoir versus reusable non-coated catheters with regard to the following outcomes: symptomatic urinary tract infections, urinary tract infection-associated bacteraemia, mortality, patient comfort and preference, quality of life, and clinical symptoms of urethral damage?

    spinal cord injuries and people over 16 who regularly self-catheterise. The primary outcome measures should be incidence of symptomatic...

    Research recommendation
    Published
    9 June 2015

  2. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.

    Technology appraisal guidance
    Published
    26 May 2021
    View recommendations

    Sections for TA704

  3. Postpartum haemorrhage: What is the most effective treatment for primary postpartum haemorrhage?

    Question Postpartum haemorrhage: What is the most effective treatment for primary postpartum haemorrhage? Any explanatory notes(if...

    Research recommendation
    Published
    6 January 2023

  4. Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (TA1103)

    Evidence-based recommendations on lorlatinib (Lorviqua) for treating ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor in adults.

    Technology appraisal guidance
    Published
    21 October 2025

    Sections for TA1103

  5. Chronic heart failure: Management of chronic heart failure in adults in primary and secondary care (CG5)

    This guideline has been updated and replaced by NICE guideline CG108.

    Withdrawn guideline

  6. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

    Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.

    Technology appraisal guidance
    Published
    17 October 2018
    View recommendations

    Sections for TA544

  7. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

    Technology appraisal guidance
    Last updated
    1 September 2025
    View recommendations

    Sections for TA924

  8. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)

    Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.

    Technology appraisal guidance
    Published
    19 December 2023
    View recommendations

    Sections for TA943

  9. Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)

    Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    13 June 2018
    View recommendations

    Sections for TA526

  10. What is the effectiveness of high-pressure non-invasive positive pressure ventilation (NIPPV) compared with continuous positive airways pressure (CPAP) flow driver as the primary mode of ventilation?

    compared with continuous positive airways pressure (CPAP) flow driver as the primary mode of ventilation? Any explanatory notes(if...

    Research recommendation
    Published
    16 August 2019

  11. Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

    Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

    Technology appraisal guidance
    Published
    17 November 2021
    View recommendations

    Sections for TA747

  12. What are the components of a decision aid to support people referred for elective joint replacement in making decisions about their treatment (for example, the type of procedure, timing and implant choice)?

    replacement surgery understand their options and make decisions about their care. Evidence from studies of decision aids for joint...

    Research recommendation
    Published
    10 August 2020

  13. Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy (MIB314)

    NICE has developed a medtech innovation briefing (MIB) on Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy .

    Medtech innovation briefing
    Published
    17 January 2023

  14. Acoustic CR Neuromodulation for adults with chronic subjective tonal tinnitus (MIB5)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Acoustic CR Neuromodulation system

    Medtech innovation briefing
    Published
    10 June 2014

  15. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued Reference number: GID-TA10099

    Technology appraisal guidance
    Discontinued